Ali Momeni1, Rana Abrishamkar2, Fatemeh Panahi1, Sepehr Eslami3, Nooshin Tavoosi4, Aryan Rafiee Zadeh1. 1. School of Medicine, Isfahan University of Medical Sciences Isfahan, Iran. 2. School of Medicine, Islamic Azad University, Najafabad Branch Isfahan, Iran. 3. Department of Orthopedics, School of Medicine, Isfahan University of Medical Sciences Isfahan, Iran. 4. Department of Midwifery, School of Nursing and Midwifery, Islamic Azad University, Shahrekord Branch Shahrekord, Iran.
Abstract
INTRODUCTION: Fingolimod is the first oral drug approved by Food and Drug Administration (FDA) of United States for treating patients with relapsing-remitting multiple sclerosis (RRMS). Fingolimod acts by immunomodulation but there are still much remained about its different effects. OBJECTIVES: The aim of this study was to evaluate the changes in hematocrit (Hct), hemoglobin (Hb), and red blood cells (RBC) of patients with MS under treatments with fingolimod. METHODS: A total number of 66 MS patients were included to our study based on certain exclusion criteria and eligibility for fingolimod oral treatment. Hct, Hb, and RBC were measured for each patient before drug administrations. Patients were treated with Fingolimod. 5 mg daily and after three months of treatments, measurements of Hct, Hb, and RBC were performed. Data were analyzed using SPSS software version 24. RESULTS: Amounts of Hct, Hb, and RBC were significantly decreased in this patient cohort. Hematocrit was decreased in all patients. Hemoglobin levels were significantly decreased in the female cohorts. Such decreases for male patients were insignificant. Red blood cell counts were also significantly decreased in patients. CONCLUSION: Accumulating line of evidence had surveys on different side effects of fngolimod but here we indicated that fingolimod will also decrease amounts of Hct, Hb, and RBC which could result further problems in patients susceptible to other diseases.
INTRODUCTION:Fingolimod is the first oral drug approved by Food and Drug Administration (FDA) of United States for treating patients with relapsing-remitting multiple sclerosis (RRMS). Fingolimod acts by immunomodulation but there are still much remained about its different effects. OBJECTIVES: The aim of this study was to evaluate the changes in hematocrit (Hct), hemoglobin (Hb), and red blood cells (RBC) of patients with MS under treatments with fingolimod. METHODS: A total number of 66 MSpatients were included to our study based on certain exclusion criteria and eligibility for fingolimod oral treatment. Hct, Hb, and RBC were measured for each patient before drug administrations. Patients were treated with Fingolimod. 5 mg daily and after three months of treatments, measurements of Hct, Hb, and RBC were performed. Data were analyzed using SPSS software version 24. RESULTS: Amounts of Hct, Hb, and RBC were significantly decreased in this patient cohort. Hematocrit was decreased in all patients. Hemoglobin levels were significantly decreased in the female cohorts. Such decreases for male patients were insignificant. Red blood cell counts were also significantly decreased in patients. CONCLUSION: Accumulating line of evidence had surveys on different side effects of fngolimod but here we indicated that fingolimod will also decrease amounts of Hct, Hb, and RBC which could result further problems in patients susceptible to other diseases.
Entities:
Keywords:
Multiple sclerosis; hematocrit; hemoglobin; red blood cells
Authors: Daniel Ontaneda; Claire Hara-Cleaver; Richard A Rudick; Jeffrey A Cohen; Robert A Bermel Journal: J Neurol Sci Date: 2012-10-03 Impact factor: 3.181
Authors: Sakari Simula; Tomi Laitinen; Tiina M Laitinen; Tuula Tarkiainen; Päivi Hartikainen; Juha Ek Hartikainen Journal: Mult Scler Date: 2015-09-11 Impact factor: 6.312
Authors: William B Rolland; Tim Lekic; Paul R Krafft; Yu Hasegawa; Orhan Altay; Richard Hartman; Robert Ostrowski; Anatol Manaenko; Jiping Tang; John H Zhang Journal: Exp Neurol Date: 2012-12-21 Impact factor: 5.330
Authors: Karthik A Jagadeesh; Kushal K Dey; Daniel T Montoro; Rahul Mohan; Steven Gazal; Jesse M Engreitz; Ramnik J Xavier; Alkes L Price; Aviv Regev Journal: Nat Genet Date: 2022-09-29 Impact factor: 41.307